Targeting TopBP1 at a Convergent Point of Multiple Oncogenic Pathways for Cancer Therapy
Document Type
Article
Publication Date
1-1-2014
Abstract
The progression of many solid tumours is driven by deregulation of multiple common pathways, particularly Rb, PI(3)K/Akt and p53. Prior studies identified TopBP1 as a key mediator for the oncogenic gain-of-function activities of mutant p53 (mutp53) in cancer. In Akt-hyperactive cancer, TopBP1 forms oligomers and represses E2F1-dependent apoptosis. Here we perform a molecular docking screening and identify a lead compound, calcein, capable of blocking TopBP1 oligomerization and p53 binding, resulting in re-activation of E2F1-dependent apoptosis and blockade of mutp53 gain-of-function. Calcein AM, the cell-permeable derivative of calcein, shows significant antitumour activity in a wide spectrum of cultured cancer cells harbouring high TopBP1 levels. These biochemical findings are recapitulated in breast cancer xenograft models. Thus, our study provides proof-of-concept evidence for targeting TopBP1, a convergent point of multiple pathways, as a cancer therapy.
Repository Citation
Chowdhury, P.,
Lin, G.,
Liu, K.,
Song, Y.,
Lin, F.,
& Lin, W.
(2014). Targeting TopBP1 at a Convergent Point of Multiple Oncogenic Pathways for Cancer Therapy. Nature Communications, 5.
https://corescholar.libraries.wright.edu/pediatrics/639
DOI
10.1038/ncomms6476
